Invitroefficacy Of Poly-Gama-Glutamic Acid Loaded Nano-Formulation Of Levofloxacin Against Brucellosis.

Abstract

Levofloxacin and Moxifloxacin are indeed a fluoroquinolone antibiotic that can be used in the treatment of brucellosis, which is caused by the bacteria of the Brucella genus. It is often used in combination with other antibiotics to treat this infection effectively. The choice of antibiotics for treating brucellosis can vary depending on factors such as the specific Brucella species causing the infection, the patient's overall health, and any antibiotic resistance patterns in the region. Levofloxacin and Moxifloxacin are one of the antibiotics that can be considered for the treatment of brucellosis, but the treatment plan should be determined by a healthcare provider who can tailor it to the individual patient's needs. In this research work, levofloxacin(LEV) and Moxifloxacin (MOX) were prepared by using of poly (gama glutamic acid) (PGA) and Polyviny alcohol (PVA) nanoparticles with the purpose of targeting drug delivery system against brucella. A thorough study has been carried out in order to optimize the preparation of  LEV, Mox-loaded polymeric nanoparticles (NPs) suitable for Brucella bacterial treatment. Changes in the preparation method, in the organic solvent nature, in the pH of the aqueous phase, or in the temperature were investigated. The physical and chemical analysis of the nanoparticles (NPs), as well as their encapsulation efficiency (EE) and the controlled release of LEV in a laboratory setting, indicated that the most effective formulation was achieved through the emulsion-solvent evaporation method utilizing dichloromethane as the organic solvent. This resulted in the production of well-suited PLGA NPs loaded with LEV. The morphology of these NPs was investigated using SEM. Their antimicrobial activities against brucella microorganisms were determined in vitro measuring the minimum inhibitory concentration (MIC). The results show that the use of these loaded LEV, MOX, PGA nanoparticles has the advantage of the slow target drug release of the antibiotic, which would permit an increase in the time period between administrations as well as to decrease the side effects of the drug.